肝移植的评估。

S. Hotta
{"title":"肝移植的评估。","authors":"S. Hotta","doi":"10.1201/9781498712699-6","DOIUrl":null,"url":null,"abstract":"Liver transplantation, one of the most technically difficult of all solid organ transplant, is effective in extending the lives of carefully selected adult patients who have end-stage organ failure due to irreversibly damaged livers. Factors that influence the outcome of liver transplantation include the specific liver disease, patient's health status, and the presence or absence of extrahepatic disease or disorder. The outcome of liver transplantation has been improved significantly by the introduction of cyclosporine and continues to be improved by the use of newer immunosuppressants such as OKT3 monoclonal antibody and antithymocyte globulin for the prevention of graft rejection. The quality of life for those who survive one or more years was generally good. Survival rates were good for patients with primary biliary cirrhosis, primary sclerosing cholangitis, hepatitis B (antigen negative), alcoholic cirrhosis, alpha-1-antitrypsin deficiency disease, Wilson's disease, and primary hemochromatosis. Patients with liver malignancies, with the possible exception of those with epithelioid hemangioendoepithelioma, had poor outcomes, while patients presenting with other end-stage liver diseases had variable outcomes.","PeriodicalId":77156,"journal":{"name":"Health technology assessment reports","volume":"1 1","pages":"1-43"},"PeriodicalIF":0.0000,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"10","resultStr":"{\"title\":\"Assessment of liver transplantation.\",\"authors\":\"S. Hotta\",\"doi\":\"10.1201/9781498712699-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Liver transplantation, one of the most technically difficult of all solid organ transplant, is effective in extending the lives of carefully selected adult patients who have end-stage organ failure due to irreversibly damaged livers. Factors that influence the outcome of liver transplantation include the specific liver disease, patient's health status, and the presence or absence of extrahepatic disease or disorder. The outcome of liver transplantation has been improved significantly by the introduction of cyclosporine and continues to be improved by the use of newer immunosuppressants such as OKT3 monoclonal antibody and antithymocyte globulin for the prevention of graft rejection. The quality of life for those who survive one or more years was generally good. Survival rates were good for patients with primary biliary cirrhosis, primary sclerosing cholangitis, hepatitis B (antigen negative), alcoholic cirrhosis, alpha-1-antitrypsin deficiency disease, Wilson's disease, and primary hemochromatosis. Patients with liver malignancies, with the possible exception of those with epithelioid hemangioendoepithelioma, had poor outcomes, while patients presenting with other end-stage liver diseases had variable outcomes.\",\"PeriodicalId\":77156,\"journal\":{\"name\":\"Health technology assessment reports\",\"volume\":\"1 1\",\"pages\":\"1-43\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1990-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health technology assessment reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1201/9781498712699-6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health technology assessment reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1201/9781498712699-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10

摘要

肝移植是所有实体器官移植中技术难度最大的移植之一,它可以有效地延长精心挑选的因肝脏不可逆损伤而终末期器官衰竭的成年患者的生命。影响肝移植结果的因素包括具体的肝脏疾病、患者的健康状况以及是否存在肝外疾病或紊乱。肝移植的预后已通过引入环孢素得到显著改善,并继续通过使用新的免疫抑制剂如OKT3单克隆抗体和抗胸腺细胞球蛋白来预防移植排斥反应。那些存活一年或更长时间的人的生活质量总体上是好的。原发性胆汁性肝硬化、原发性硬化性胆管炎、乙型肝炎(抗原阴性)、酒精性肝硬化、α -1-抗胰蛋白酶缺乏症、威尔逊氏病和原发性血色素沉着症患者的生存率较高。肝恶性肿瘤患者(上皮样血管内皮瘤患者可能除外)预后较差,而其他终末期肝病患者预后不同。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Assessment of liver transplantation.
Liver transplantation, one of the most technically difficult of all solid organ transplant, is effective in extending the lives of carefully selected adult patients who have end-stage organ failure due to irreversibly damaged livers. Factors that influence the outcome of liver transplantation include the specific liver disease, patient's health status, and the presence or absence of extrahepatic disease or disorder. The outcome of liver transplantation has been improved significantly by the introduction of cyclosporine and continues to be improved by the use of newer immunosuppressants such as OKT3 monoclonal antibody and antithymocyte globulin for the prevention of graft rejection. The quality of life for those who survive one or more years was generally good. Survival rates were good for patients with primary biliary cirrhosis, primary sclerosing cholangitis, hepatitis B (antigen negative), alcoholic cirrhosis, alpha-1-antitrypsin deficiency disease, Wilson's disease, and primary hemochromatosis. Patients with liver malignancies, with the possible exception of those with epithelioid hemangioendoepithelioma, had poor outcomes, while patients presenting with other end-stage liver diseases had variable outcomes.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信